Format

Send to

Choose Destination
Hum Vaccin. 2010 Jun;6(6):467-75. Epub 2010 Jun 1.

Acceptability of prophylactic human papillomavirus vaccination among adult men.

Author information

1
Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI, USA. brenda@crch.hawaii.edu

Abstract

OBJECTIVES:

HPV vaccine acceptability was examined as part of a cohort study of HPV infection among adult males.

RESULTS:

Overall, 69% of men reported that they were likely or very likely to be vaccinated against HPV if a prophylactic vaccine were available. Men most frequently cited side effects (69%), efficacy (65%), and safety (63%) as the major factors that would influence their decision to be vaccinated against HPV. Issues of vaccine costs and efficacy were important considerations for men of vaccine-eligible ages (18-26 years). Men who cited cost as a major factor in their HPV vaccine decisions and those indicating cost as a potential barrier had greater intention to be vaccinated. Heterosexual men had less intention to be vaccinated compared to men who have sex with men.

METHODS:

Between July 2004 and June 2007, 445 adult males aged ≥18 years were enrolled primarily from a university-based population. A structured questionnaire addressed HPV vaccine awareness, attitudes, and intention to be vaccinated.

CONCLUSION:

Acceptability of HPV vaccination among males is generally high. Costs and sexual history may influence vaccine utilization.

PMID:
20671442
PMCID:
PMC3010761
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center